focus -WSS

focus

author：comprehensive 2025-09-30 12:11:29 - browse：8645

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Device maker Teleflex to acquire urology company for $600M

WSS

As AI regulations shape up, health tech startups beg for clarity

New study raises questions about niacin and heart health

FDA warns medical device makers about rise in fabricated data

Obamacare plans could cover weight loss drugs

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Hospitals are piloting generative AI tools as regulators play catch

entertainment

focus

hotspot

Walensky prepares to leave CDC — and Congress — behind

The battle over 'scope creep' and who gets to be called 'doctor'

As demand for Covid shots wanes, Moderna seeks its next success

Reporting on presidential health from Reagan to Trump and Biden

Medicare proposal to cover medical devices draws a mixed reaction

Why patients can’t get everything they want on drug pricing

23andMe had bad news about my health. I wish a person had delivered it

CDC Director Mandy Cohen on transparency, trust, and health

Guidelines to prevent youth baseball injuries need more muscle

A new drug could help frostbite victims avoid its ravages

explore

Ukraine seeks to reclaim its role as a hub for clinical trials

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

In 'major milestone,' FDA approves first cell therapy for solid tumors

Senate panel puts off hardest PBM reforms for another day

Abridge raises $150m as clinical notes automation market heats up

Will the FTC rein in IQVIA's health data empire?

explore

focus

entertainment

entertainment